CTI BIOPHARMA CORP has a total of 24 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2006. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD, CENTAURUS BIOPHARMA CO LTD and NEUROCRINE BIOSCIENCES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | Australia | 3 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Hong Kong | 3 | |
#5 | Taiwan | 3 | |
#6 | Argentina | 1 | |
#7 | Israel | 1 | |
#8 | Japan | 1 | |
#9 | Malaysia | 1 | |
#10 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Lee Cheng Hsia Angeline | 14 |
#2 | William Anthony Deodaunia | 14 |
#3 | Sun Eric T | 7 |
#4 | Poulsen Anders | 7 |
#5 | Nagaraj Harish Kumar Mysore | 7 |
#6 | Dymock Brian | 7 |
#7 | Tan Yee Ling Evelyn | 7 |
#8 | Blanchard Stephanie | 6 |
#9 | Yu Xuezhong | 4 |
#10 | Betts Brian C | 4 |
Publication | Filing date | Title |
---|---|---|
US2017112846A1 | Oxygen linked pyrimidine derivatives | |
WO2017058950A1 | Methods of treating transplant rejection | |
AU2009294311A1 | Platinum complex with antitumor activity | |
TW201418263A | Oxygen linked pyrimidine derivatives |